Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07112274) titled 'Empagliflozin on Patients With Preserved Heart Failure' on Aug. 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Damanhour University

Condition: Heart Failure

Intervention: Drug: Empagliflozin 10 MG

Recruitment Status: Not recruiting

Phase: N/A

Date of First Enrollment: October 1, 2022

Target Sample Size: 50

Countries of Recruitment: Egypt

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07112274

Published by HT Digital Content Services with p...